Multifocal Atrial Tachycardia

Multiple concurrent ectopic pacemakers

• Multiple atrial sites develop enhanced automaticity simultaneously, creating competition for atrial depolarization
• Abnormal diastolic depolarization occurs in subsidiary pacemaker cells due to increased intracellular calcium cycling and altered potassium channel function
• Triggered activity from afterdepolarizations (both early and delayed) contributes to ectopic impulse generation
• Abnormal automaticity in atrial myocardium is enhanced by sympathetic stimulation, hypoxemia, and metabolic derangements

Altered electrophysiologic substrate

• Atrial tissue exhibits nonuniform refractory periods and conduction velocities, facilitating multiple simultaneous depolarizations
• Chronic pulmonary disease produces atrial dilation and fibrosis, increasing heterogeneity of conduction properties
• Increased catecholamine sensitivity in ischemic or inflamed atrial tissue lowers the threshold for automatic impulse formation
• Abnormal intracellular calcium handling from underlying disease increases spontaneous diastolic depolarization rates

AV nodal conduction variability

• The AV node exhibits variable conduction block and adaptive properties, allowing selective transmission of some ectopic atrial impulses
• Functional refractory period of the AV node is prolonged by certain medications (beta-blockers, calcium channel blockers) and autonomic tone, creating a filtering effect
• PR interval varies based on which ectopic atrial focus activates and the AV nodal conduction state at that moment
• Irregular ventricular response results from the unpredictable sequence of atrial ectopic beats and AV nodal penetration

Pulmonary disease (most common)

• Chronic obstructive pulmonary disease (COPD) with acute exacerbation
• Acute pneumonia and respiratory tract infections
• Pulmonary embolism and acute hypoxemia
• Cor pulmonale and chronic hypoxic states
• Cystic fibrosis and severe bronchiectasis

Cardiac disease

• Acute coronary syndrome and myocardial ischemia
• Congestive heart failure (any etiology)
• Valvular heart disease and cardiomyopathy
• Myocarditis and pericarditis
• Atrial septal defect and other structural abnormalities

Metabolic and toxic factors

• Severe hypokalemia and hypomagnesemia
• Hypoxemia and hypercapnia
• Theophylline toxicity and other xanthine derivatives
• Excessive catecholamine administration or endogenous excess
• Amphetamine and cocaine use

Other systemic conditions

• Sepsis and systemic inflammatory states
• Thyrotoxicosis and hyperthyroidism
• Acute decompensated renal failure
• Diabetic ketoacidosis and other metabolic acidoses
• Advanced malignancy

Medications

• Beta-adrenergic agonists (albuterol, epinephrine)
• Digitalis toxicity (classic association)
• Corticosteroids and sympathomimetic agents
• Tricyclic antidepressants at toxic levels

Arrhythmia-related symptoms

• Palpitations, often described as irregular and rapid fluttering
• Dyspnea, particularly pronounced in patients with baseline pulmonary disease
• Chest discomfort or angina in susceptible patients
• Presyncope and syncope (less common, usually with rapid ventricular rates)
• Asymptomatic presentation detected incidentally on monitoring (frequent)

Physical examination findings

• Irregular rapid pulse with variable rate and rhythm irregularity
• Irregular JVD without the regular "cannon" waves characteristic of AV dissociation
• Variable intensity of the first heart sound (S1) due to changing PR intervals
• Tachycardia with rates typically 100-150 bpm, rarely exceeding 200 bpm
• Signs of underlying disease: wheezing/rales (pulmonary disease), peripheral edema, displaced PMI (heart failure)
• Signs of hemodynamic compromise: hypotension, decreased perfusion, altered mental status (usually only with sustained rates >150 bpm in elderly patients)

Symptoms correlating with underlying disease

• Worsening dyspnea from acute COPD exacerbation
• Orthopnea and paroxysmal nocturnal dyspnea from concurrent heart failure
• Chest pain and shortness of breath from acute MI or PE
• Confusion or altered mental status from infection or metabolic derangement

12-lead electrocardiogram (gold standard)

• Minimum three different P-wave morphologies with different axes and configurations (required for diagnosis)
• PR intervals vary significantly between different P waves
• P-P intervals are irregular and variable
• QRS complexes are narrow (<120 ms) and regular or variable depending on AV nodal conduction
• Baseline isoelectric line visible between P waves (distinguishes from atrial flutter)
• Absence of a single dominant pacemaker frequency
• ECG findings must be present during a rhythm strip of adequate duration (at least 10-15 seconds recommended)

Diagnostic criteria (all required)

• Heart rate ≥100 bpm
• Three or more distinct P-wave morphologies
• Irregular PR intervals and/or RR intervals
• Absence of isoelectric baseline between P waves (distinguishes from chaotic atrial rhythm)
• Baseline sinus rhythm rate typically normal or slow between episodes in paroxysmal MAT

Ambulatory monitoring

• 24-48 hour Holter monitor or event monitor documents arrhythmia in paroxysmal cases
• Continuous telemetry in hospitalized patients confirms diagnosis and assesses frequency
• Extended monitoring may reveal triggering patterns (diurnal variation, relation to symptoms)

Laboratory evaluation

• Serum electrolytes with special attention to potassium (<3.5 mEq/L is major trigger) and magnesium (<2 mg/dL increases risk)
• Arterial blood gas to assess oxygenation (PaO2) and acid-base status (hypercapnia and acidosis are contributors)
• Troponin and BNP to evaluate for myocardial ischemia and heart failure
• TSH and free T4 if thyroidism suspected clinically
• Theophylline level if patient on this medication
• Digoxin level if digitalis toxicity suspected (therapeutic range 0.5-2.0 ng/mL; toxicity often occurs >2.0 ng/mL)
• Complete metabolic panel including renal function
• Complete blood count to assess for infection or anemia

Transthoracic echocardiography

• Evaluates left and right ventricular function and chamber dimensions
• Assesses for structural heart disease, valvular abnormalities, or thrombus
• Documents left atrial enlargement (common in MAT)
• Estimates right ventricular systolic pressure for cor pulmonale assessment
• Not required for diagnosis but helpful for prognostication and identifying treatable causes

Chest radiography

• Identifies underlying pulmonary pathology (pneumonia, COPD changes, pulmonary edema, PE)
• Assesses cardiac silhouette size
• Evaluates pulmonary vascular congestion

Electrophysiology study

• Not diagnostic purpose (clinical diagnosis made by ECG)
• Rarely performed for MAT
• May be considered if diagnosis uncertain or to exclude other arrhythmias
• Demonstrates multiple atrial foci with stimulation

Differential diagnosis considerations

• Atrial fibrillation: Absent P waves, completely irregular baseline, often faster rates; may coexist with MAT
• Atrial flutter: Regular sawtooth baseline, regular ventricular rate with variable block; single dominant frequency
• Sinus tachycardia with ectopic beats: Single consistent P-wave morphology in sinus beats
• Chaotic atrial rhythm: Markedly irregular baseline without distinct isoelectric periods; very rare

Management of underlying disease (cornerstone of therapy)

• Acute COPD exacerbation: Oxygen therapy, bronchodilators, corticosteroids, antibiotics
• Pneumonia: Appropriate antibiotic therapy and supportive care
• Heart failure: Diuretics, ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists
• Hypoxemia: Supplemental oxygen targeting SpO2 >90-92%; addressing underlying pulmonary disease
• Infection/sepsis: Targeted antimicrobial therapy and source control
• Thyrotoxicosis: Antithyroid medications or beta-blockade
• Treatment of underlying disease resolves MAT in 60-70% of cases

Electrolyte correction (critical intervention)

• Potassium supplementation: Target serum K+ >4.0 mEq/L (ideally 4.5-5.0 mEq/L) for arrhythmia suppression
• Magnesium supplementation: Target Mg2+ >2.0 mg/dL; IV or oral repletion depending on severity
• Electrolyte abnormalities are present in >50% of MAT cases
• Repletion often terminates or significantly reduces MAT frequency

First-line pharmacologic treatment

• Verapamil 120-360 mg daily in divided doses (immediate-release) or 120-480 mg daily (sustained-release)
• Diltiazem 120-360 mg daily in divided doses (immediate-release) or 120-540 mg daily (sustained-release)
• Mechanism: AV nodal conduction slowing reduces ventricular rate; negative chronotropic and inotropic effects reduce ectopic automaticity
• Efficacy: Effective in 60-70% of patients; reduces ventricular rate and occasionally terminates arrhythmia
• Cautions: Contraindicated in decompensated heart failure (negative inotrope); monitor for bradycardia and hypotension
• Onset: 30 minutes to 2 hours for oral formulations

• Metoprolol 25-100 mg BID or 100-400 mg daily (extended-release)
• Atenolol 25-100 mg daily
• Propranolol 80-240 mg daily in divided doses
• Mechanism: Reduces sympathetic tone, decreases automaticity, slows AV conduction
• Efficacy: Effective in 50-60% of MAT cases; particularly useful if concurrent hypertension or CAD
• Cautions: Contraindicated in decompensated COPD or asthma; use with extreme caution in hemodynamic compromise
• Note: Often avoided in acute COPD exacerbation setting despite being effective for arrhythmia control

Second-line pharmacologic treatment

• Loading dose: 0.5-1.0 mg IV/PO divided over 24 hours
• Maintenance dose: 0.125-0.25 mg daily (adjust for renal function)
• Mechanism: Vagomimetic effects increase AV nodal refractoriness; positive inotropic effect; direct automaticity suppression
• Efficacy: Effective in 50-60% of cases; particularly useful in MAT with concurrent heart failure (provides inotropic support)
• Important considerations: Narrow therapeutic window; requires monitoring of serum levels (therapeutic 0.5-2.0 ng/mL); toxicity common
• Digoxin toxicity: PVCs, PACs, second/third degree block, nausea, visual disturbances; hyperkalemia is major risk factor
• Cautions: Contraindicated with hypokalemia (toxicity risk); ineffective if hypokalemia or hypomagnesemia present; renal dose adjustment required

• Loading: 600 mg daily for 1-2 weeks, then reduce to maintenance
• Maintenance: 100-400 mg daily
• Use: Reserved for refractory MAT or when combination therapy needed
• Mechanism: Class IA, IB, IC, and III properties; beta-blocking and calcium channel blocking effects
• Efficacy: Very effective but reserved for refractory cases due to toxicity profile
• Cautions: Multiple drug interactions; organ toxicity (thyroid, liver, pulmonary, cardiac); long half-life
• Disadvantage: Not recommended as first-line due to side effect profile in setting of underlying pulmonary disease (pulmonary toxicity risk)

• Theophylline toxicity management: Cease theophylline; activated charcoal if recent ingestion; consider hemodialysis for severe toxicity
• Flecainide: Class IC antiarrhythmic; limited data; class III agents generally preferred

Non-pharmacological measures

• Oxygen therapy: Essential if hypoxemic; target SpO2 >90-92%
• Respiratory therapy: Chest physiotherapy, mechanical ventilation if needed for respiratory failure
• Fluid management: Cautious approach; avoid volume overload in heart failure but ensure adequate hydration in dehydration
• Activity restriction: During acute episodes; cardiac monitoring in hospital setting
• Stress reduction: Minimize acute illness and metabolic stress

Catheter ablation

• Generally NOT recommended for MAT (unlike other SVTs)
• Multiple atrial foci make ablation technically challenging and ineffective
• High recurrence rate after ablation
• Reserved for rare refractory cases after medical optimization
• May be considered if single dominant focus identified on electrophysiology study (atypical presentation)

Monitoring and follow-up

• Continuous telemetry in hospitalized patients until arrhythmia controlled and underlying disease improving
• Serial ECGs to document arrhythmia resolution and assess for treatment-related changes
• Electrolyte monitoring: Daily or every 2-3 days until normalized and stable
• Echocardiography follow-up: If structural disease identified
• Outpatient cardiology follow-up: After discharge to assess medication tolerance and adjust therapy
• 24-48 hour Holter monitor or event monitor: Prior to discharge to document arrhythmia burden reduction

Hemodynamic compromise

• Rapid ventricular response (>150 bpm sustained) can precipitate acute heart failure, myocardial ischemia, or hypotension
• Risk increased in elderly patients and those with baseline LV dysfunction
• Presents with hypotension, decreased mental status, acute pulmonary edema
• Management: IV medications for rate control (verapamil or diltiazem IV); synchronized cardioversion for hemodynamically unstable patients with sustained rates >150 bpm; treatment of underlying disease

Acute decompensated heart failure

• Uncontrolled MAT with rapid ventricular response can precipitate acute pulmonary edema, especially in patients with reduced ejection fraction
• Tachycardia reduces diastolic filling time and increases myocardial oxygen demand
• Management: IV diuretics, vasodilators, inotropes if cardiogenic shock; rate control with IV calcium channel blocker or digoxin (latter preferred if systolic dysfunction present); mechanical support if refractory

Myocardial ischemia and infarction

• Sustained tachycardia increases myocardial oxygen demand; may precipitate angina or MI in susceptible patients
• Particularly concerning in patients with underlying coronary artery disease or acute coronary syndrome
• Management: Urgent coronary angiography if ACS suspected; rate control and medical optimization; revascularization if indicated

Thromboembolism (uncommon but possible)

• Despite irregular rhythm, MAT carries lower thromboembolic risk

• The buzzword triad: three or more distinct P-wave morphologies, varying PR intervals, and an irregularly irregular ventricular response at a rate ≥100 bpm. The identical morphology pattern at a rate <100 bpm is wandering atrial pacemaker — same mechanism, different rate cutoff.
• The association examiners test: an elderly patient with a COPD exacerbation (hypoxemia, hypercapnia, beta-agonist and theophylline exposure) who develops an irregular tachycardia. Hypomagnesemia and hypokalemia are the metabolic co-triggers worth naming.
• Single best next step: treat the precipitant, not the rhythm — oxygenation/ventilation, bronchodilators and steroids for the exacerbation, and repletion of magnesium and potassium. The 2015 ACC/AHA/HRS supraventricular tachycardia guideline makes management of the underlying condition the primary recommendation in MAT.
• Drug of choice when rate control is still needed: a nondihydropyridine calcium channel blocker (verapamil or diltiazem), favored over beta blockers in bronchospastic lung disease. The ACC/AHA/HRS guideline lists both verapamil/diltiazem and a beta blocker as reasonable, but beta blockade is often deferred during active bronchospasm.
• The classic distractor — cardioversion: MAT arises from enhanced automaticity at multiple foci, not a reentrant circuit, so there is no circuit to depolarize; synchronized cardioversion does not convert the arrhythmia and any apparent response is transient. Choose rate control and treatment of the underlying illness instead.
• The second classic distractor — adenosine: it will not terminate MAT because the AV node is a bystander. Transient AV block may unmask the multiple P-wave morphologies, which is diagnostic, not therapeutic.
• Distinguish from atrial fibrillation: both are irregularly irregular, but MAT has discrete, organized P waves before every QRS. Mistaking MAT for AF leads to the wrong exam answer of anticoagulation or rhythm control.
• Ablation is not the answer: unlike AVNRT, AVRT, or focal atrial tachycardia, MAT has no single ablatable focus.